[ad_1]
Basking Ridge, NJ – 
(NewMediaWire) – June 03, 2021 – Timber Pharmaceuticals, Inc.
(“Timber” or the “Company”) (NYSE American: TMBR), a
biopharmaceutical company focused on the development and commercialization of
treatments for rare and orphan dermatologic diseases, today announced that on
June 3, 2021 its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was
convened without a quorum. As a result, in order to provide stockholders
additional time within which to vote their eligible shares to establish a
quorum, the Annual Meeting was adjourned.
The adjourned meeting
will be held at 1:00 p.m. ET on Thursday, July 1, 2021 at the following url: www.virtualshareholdermeeting.com/TMBR2021. The record date for the Annual Meeting remains
April 12, 2021.
About Timber
Pharmaceuticals, Inc.
Timber
Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development
and commercialization of treatments for rare and orphan dermatologic diseases.
The Company’s investigational therapies have proven mechanisms-of-action backed
by decades of clinical experience and well-established CMC (chemistry,
manufacturing and control) and safety profiles. The Company is initially
focused on developing non-systemic treatments for rare dermatologic diseases
including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and scleroderma. For more information, visit www.timberpharma.com.
For more information, contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chairman and Chief Executive Officer
jkoconis@timberpharma.com
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com
Media
Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
[ad_2]
